<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38547037</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>12</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged &#x2265;18 Years with Immunocompromising Conditions - VISION Network, September 2023-February 2024.</ArticleTitle><Pagination><StartPage>271</StartPage><EndPage>276</EndPage><MedlinePgn>271-276</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7312a5</ELocationID><Abstract><AbstractText>In September 2023, CDC's Advisory Committee on Immunization Practices recommended updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccination for all persons aged &#x2265;6 months to prevent COVID-19, including severe disease. As with past COVID-19 vaccines, additional doses may be considered for persons with immunocompromising conditions, who are at higher risk for severe COVID-19 and might have decreased response to vaccination. In this analysis, vaccine effectiveness (VE) of an updated COVID-19 vaccine dose against COVID-19-associated hospitalization was evaluated during September 2023-February 2024 using data from the VISION VE network. Among adults aged &#x2265;18 years with immunocompromising conditions, VE against COVID-19-associated hospitalization was 38% in the 7-59 days after receipt of an updated vaccine dose and 34% in the 60-119 days after receipt of an updated dose. Few persons (18%) in this high-risk study population had received updated COVID-19 vaccine. All persons aged &#x2265;6 months should receive updated 2023-2024 COVID-19 vaccination; persons with immunocompromising conditions may get additional updated COVID-19 vaccine doses &#x2265;2 months after the last recommended COVID-19 vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Link-Gelles</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Rowley</LastName><ForeName>Elizabeth A K</ForeName><Initials>EAK</Initials></Author><Author ValidYN="Y"><LastName>DeSilva</LastName><ForeName>Malini B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Dascomb</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Nicola P</ForeName><Initials>NP</Initials></Author><Author ValidYN="Y"><LastName>Grannis</LastName><ForeName>Shaun J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Ong</LastName><ForeName>Toan C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Zachary A</ForeName><Initials>ZA</Initials></Author><Author ValidYN="Y"><LastName>Fleming-Dutra</LastName><ForeName>Katherine E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>Charlene E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Akinsete</LastName><ForeName>Omobosola</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Bride</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sheffield</LastName><ForeName>Tamara</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Naleway</LastName><ForeName>Allison L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Zerbo</LastName><ForeName>Ousseny</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Fireman</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Goddard</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Dixon</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>Rogerson</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Fadel</LastName><ForeName>William F</ForeName><Initials>WF</Initials></Author><Author ValidYN="Y"><LastName>Duszynski</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Suchitra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Barron</LastName><ForeName>Michelle A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Reese</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Ball</LastName><ForeName>Sarah W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Dunne</LastName><ForeName>Margaret M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Okwuazi</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Ami B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Wiegand</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Tenforde</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Payne</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Brian E. Dixon reports institutional support from the National Institutes of Health (NIH) and the U.S. Department of Veterans Affairs and royalties from Elsevier, Inc. for a book on health information technology and from Springer Nature for a book on health information technology. Nicola P. Klein reports institutional support from Sanofi Pasteur, Merck, Pfizer, Seqiris, and GSK; uncompensated membership on an expert panel for a planned Hepatitis E Phase II vaccine clinical trial among pregnant women in Pakistan, sponsored by the International Vaccine Institute; unpaid membership on the Western States COVID-19 Scientific Safety Review Workgroup, the Board on Population Health and Public Health Practice, the National Academies of Science, Engineering and Medicine, and the National Vaccine Advisory Committee Safety Subcommittee. Charlene E. McEvoy reports grants or contracts from NIH, the Department of Defense, Patient-Centered Outcomes Research Institute, Astra Zeneca, and GSK; payment or honorarium from Pri-Med for a lecture on incorporation of ACT and CAT into electronic health records to improve outcomes in patients with asthma and chronic obstructive pulmonary disease; and uncompensated participation on the American Lung Association of Minnesota Board, the Minnesota Department of Health Long COVID Advisory Committee, and the Minnesota Department of Health Asthma Care Advisory Committee. Tamara Sheffield reports uncompensated membership on CDC&#x2019;s Advisory Committee on Immunization Practices Influenza Vaccine Work Group, chairmanship of the Utah Adult Immunization Coalition vaccine quality improvement and advocacy group, and membership on the Utah Department of Health and Human Services Scientific Advisory Committee on Vaccines. Ousseny Zerbo reports a grant from the National Institute of Allergy and Infectious Diseases. Suchitra Rao reports grants from Biofire and GSK. No other potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>18</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>28</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38547037</ArticleId><ArticleId IdType="pmc">PMC10986819</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7312a5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Regan JJ, Moulia DL, Link-Gelles R, et al. Use of updated COVID-19 vaccines 2023&#x2013;2024 formula for persons aged &#x2265;6 months: recommendations of the Advisory Committee on Immunization Practices&#x2014;United States, September 2023. MMWR Morb Mortal Wkly Rep 2023;72:1140&#x2013;6. 10.15585/mmwr.mm7242e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7242e1</ArticleId><ArticleId IdType="pmc">PMC10602621</ArticleId><ArticleId IdType="pubmed">37856366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022;376:e068632. 10.1136/bmj-2021-068632</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068632</ArticleId><ArticleId IdType="pmc">PMC8889026</ArticleId><ArticleId IdType="pubmed">35236664</ArticleId></ArticleIdList></Reference><Reference><Citation>DeCuir J, Payne AB, Self WH, et al.; CDC COVID-19 Vaccine Effectiveness Collaborators. Interim effectiveness of updated 2023&#x2013;2024 (monovalent XBB.1.5) COVID-19 vaccines against COVID-19&#x2013;associated emergency department and urgent care encounters and hospitalization among immunocompetent adults aged &#x2265;18 years&#x2014;VISION and IVY networks, September 2023&#x2013;January 2024. MMWR Morb Mortal Wkly Rep 2024;73:180&#x2013;8. 10.15585/mmwr.mm7308a5</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7308a5</ArticleId><ArticleId IdType="pmc">PMC10907041</ArticleId><ArticleId IdType="pubmed">38421945</ArticleId></ArticleIdList></Reference><Reference><Citation>Britton A, Embi PJ, Levy ME, et al. Effectiveness of COVID-19 mRNA vaccines against COVID-19&#x2013;associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance&#x2014;VISION network, 10 states, December 2021&#x2013;August 2022. MMWR Morb Mortal Wkly Rep 2022;71:1335&#x2013;42. 10.15585/mmwr.mm7142a4</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7142a4</ArticleId><ArticleId IdType="pmc">PMC9590295</ArticleId><ArticleId IdType="pubmed">36264840</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of bivalent mRNA vaccine durability in preventing COVID-19&#x2013;associated hospitalization and critical illness among adults with and without immunocompromising conditions&#x2014;VISION network, September 2022&#x2013;April 2023. MMWR Morb Mortal Wkly Rep 2023;72:579&#x2013;88. 10.15585/mmwr.mm7221a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7221a3</ArticleId><ArticleId IdType="pmc">PMC10231940</ArticleId><ArticleId IdType="pubmed">37227984</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher AM, Schlauch D, Mulloy M, et al. Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States. Clin Transplant 2021;35:e14216. 10.1111/ctr.14216</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ctr.14216</ArticleId><ArticleId IdType="pmc">PMC7883091</ArticleId><ArticleId IdType="pubmed">33406279</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>